COMMUNIQUÉS West-GlobeNewswire

Press Release: Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded
30/10/2026
Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded October 30, 2026 Q3 sales growth of 14.3% at CER 1 and business earnings per share (EPS) 2 of €3.55 Pharma launches sales increased by 31 [...]
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter 2026
30/10/2026
Tokyo, Japan and Cambridge, UK, 30 October 202 6 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter ended 30 [...]
Fangzhou Honored with Digital Intelligence Leadership Award at Tencent Summit, Expands Healthcare AI Partnership with Tencent Health
30/10/2026
SHANGHAI, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, received the “Digital-intelligence Leadership Award- [...]
Vivoryon Therapeutics N.V. to Report Q3 2026 Financial Results on November 5, 2026
30/10/2026
Vivoryon Therapeutics N.V. to Report Q3 2026 Financial Results on November 5, 2026 Halle (Saale) / Munich, Germany, October 30, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a [...]
Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution
30/10/2026
This international award, honoring “the best of the best” in medical innovation, represents yet another important external recognition of AI-Immunology™ COPENHAGEN, Denmark, October 30, 2026 - Evaxion A/S (NASDAQ: EVAX [...]
Tangram annonce l’administration du TGM-148 au premier participant de l’essai de phase 1 évaluant le TGM-148, un nouveau médicament expérimental à ARNi contre les troubles hémorragiques
30/10/2026
Le TGM-148 est conçu pour associer une efficacité hémostatique à un profil de sécurité favorable et une faible contrainte thérapeutique Le deuxième actif de Tangram à entrer en phase clinique en 2026 L’essai de phase 1 [...]
2026 InLight Foundation Stanford Frontier Dialogue: From Nobel Optogenetics to Mind-Light Contemplation, Cross-Disciplinary Experts Explore New Frontiers in Consciousness Regulation
30/10/2026
PALO ALTO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Following the awarding of the 2026 Nobel Prize in Physiology or Medicine to pioneers in optogenetics, the InLight Foundation concluded its "Consciousness and Science [...]
InnoCare Announces First Subject Dosed in Clinical Trial of TL1A/IL-23p19 Bispecific Antibody ICP-B161 in China
30/10/2026
BEIJING, Oct. 30, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first [...]
Aspen Neuroscience Announces Pricing of Initial Public Offering
30/10/2026
SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Aspen Neuroscience, Inc. (Nasdaq: ASPE), a clinical-stage regenerative medicine biotechnology company developing autologous cell therapies for Parkinson’s disease (PD), today [...]
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
29/10/2026
Company to issue press release before market open; conference call to follow at 8:30 a.m. ET WILMINGTON, Del., Oct. 29, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a [...]
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
29/10/2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that it will report third quarter 2026 financial results after market close on Thursday [...]
BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
29/10/2026
- $353.2 million in total third quarter revenues, primarily comprised of $253.2 million of U.S. Attruby net product revenue (up approximately $31 million sequentially and $145 million year over year). Loss from [...]
Alignment Healthcare Reports Third Quarter 2026 Results, Updates Full-Year Outlook
29/10/2026
Reports third-quarter revenue of $ 1.36 billion, representing 36.7% year-over-year growth Grows health plan membership 31.2% year-over-year to 301,200 members Issues fourth-quarter guidance and lowers full-year 2026 [...]
Merit Medical Acquires Solo Pace, Inc., Expanding Its Cardiac Therapies Platform with Innovative TAVR Pacing Technology
29/10/2026
Solo Pace, Inc. specializes in temporary pacing solutions and systems designed for transcatheter heart valve procedures, including transcatheter aortic valve replacement procedures SOUTH JORDAN, Utah, Oct. 29, 2026 ( [...]
Merit Medical Reports Third Quarter 2026 Results: Delivers 9% Organic Constant Currency Revenue Growth and Raises Full-Year 2026 Guidance
29/10/2026
Financial Highlights† Reported revenue of $416.2 million, up 8.4% Constant currency revenue* and constant currency revenue, organic* up 8% and up 9%, respectively GAAP operating margin of 14.1%, compared to 11.1% in [...]
CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026
29/10/2026
SARATOGA, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced [...]
Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
29/10/2026
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, [...]
Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
29/10/2026
- Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - - Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N=55) expected in the first half of 2027 [...]
FOXO TECHNOLOGIES INC. ANNOUNCES AGREEMENTS TO ACQUIRE PREFERRED STOCK CARRYING MAJORITY VOTING POWER IN LUDWIG ENTERPRISES, INC.
29/10/2026
WEST PALM BEACH, FL, Oct. 29, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc . (OTC: FOXO) (“FOXO” or the “Company”) today announced that it has entered into Stock Purchase Agreements to acquire shares of preferred [...]

Pages